These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29374261)

  • 1. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
    Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
    Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
    Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
    J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors.
    Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
    Biochem Biophys Res Commun; 2019 Feb; 509(4):943-948. PubMed ID: 30648556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.
    Domaoal RA; McMahon M; Thio CL; Bailey CM; Tirado-Rives J; Obikhod A; Detorio M; Rapp KL; Siliciano RF; Schinazi RF; Anderson KS
    J Biol Chem; 2008 Feb; 283(9):5452-9. PubMed ID: 17962184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.
    Yasutake Y; Hattori SI; Kumamoto H; Tamura N; Maeda K; Mitsuya H
    Sci Rep; 2024 Jul; 14(1):15742. PubMed ID: 38977798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
    Walsh AW; Langley DR; Colonno RJ; Tenney DJ
    PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
    Rawal RK; Konreddy AK; Chu CK
    Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.
    Nakamura A; Tamura N; Yasutake Y
    Acta Crystallogr F Struct Biol Commun; 2015 Nov; 71(Pt 11):1384-90. PubMed ID: 26527265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis B virus polymerase by entecavir.
    Langley DR; Walsh AW; Baldick CJ; Eggers BJ; Rose RE; Levine SM; Kapur AJ; Colonno RJ; Tenney DJ
    J Virol; 2007 Apr; 81(8):3992-4001. PubMed ID: 17267485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
    Takamatsu Y; Tanaka Y; Kohgo S; Murakami S; Singh K; Das D; Venzon DJ; Amano M; Higashi-Kuwata N; Aoki M; Delino NS; Hayashi S; Takahashi S; Sukenaga Y; Haraguchi K; Sarafianos SG; Maeda K; Mitsuya H
    Hepatology; 2015 Oct; 62(4):1024-36. PubMed ID: 26122273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.
    Tchesnokov EP; Obikhod A; Schinazi RF; Götte M
    J Biol Chem; 2008 Dec; 283(49):34218-28. PubMed ID: 18940786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
    Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
    Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
    Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
    Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
    Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.